Bearsden Receives $1.7 MM in Research Grants

Search Blogs that Mention this News Release
Click this link to view linked Bookmarking Services
Click this link to view linked Blogging Services
Bearsden Receives $1.7 MM in Research Grants
    ASTON, Pa., Nov. 9 /PRNewswire/ -- The following was issued today by
Bearsden Bio, Inc.:

    Bearsden Bio, Inc. has received one Phase II SBIR grant and one CRADA from
the US National Institutes of Health. The funding is going towards the study
of its kainate receptor antagonist (SYM 2081) in chronic pain and the
understanding of the role of glutamate receptors in Alzheimer's Disease and
Down's Syndrome.
    The SBIR grant focuses on the treatment of acute and chronic pain with SYM
2081 and on the compound's bioavailability, pharmacokinetic and toxicity
profile.  The CRADA will test the effects of receptor subtype specific
antagonists in nerve transmission and animal models of diseases, such as
Alzheimer's and Down's.  The three compounds that are specific for the
glutamate receptor subtypes are SYM 2081 for the kainate receptor, SYM 2198
for the AMPA receptor and ACPC for the NMDA receptor.
    Our goal is to progress the project through preclinical testing to the
clinical stage and then partner for the clinical development.  We are
continuing the work on glutamate receptors and brain.  We are currently
talking to potential corporate partners and discussing the co-development of
the pain compound as well as the depression compound through the clinic.
    Bearsden is a biopharmaceutical company with a broad based technology in
nucleic acid and rational drug design.  The company's chemists are experts at
designing, synthesizing and manufacturing antisense and medicinal chemistry
products for research, diagnostic and therapeutic purposes.  The company has
12 patent or patent applications covering new technologies and composition of
matter and is focusing its efforts into bringing the technologies and lead
compounds to market.
    Bearsden plans to grow internally as well as through acquisitions to be at
the forefront of biotechnology based drug design, development and
manufacturing and become the partner of choice for pharmaceutical companies to
collaborate in their development efforts of drug intermediates and drug leads.
SOURCE Bearsden Bio, Inc.